ATE252901T1 - Arzneimittel zur behandlung von entzündlichen herzkrankheiten - Google Patents

Arzneimittel zur behandlung von entzündlichen herzkrankheiten

Info

Publication number
ATE252901T1
ATE252901T1 AT96301438T AT96301438T ATE252901T1 AT E252901 T1 ATE252901 T1 AT E252901T1 AT 96301438 T AT96301438 T AT 96301438T AT 96301438 T AT96301438 T AT 96301438T AT E252901 T1 ATE252901 T1 AT E252901T1
Authority
AT
Austria
Prior art keywords
treatment
heart disease
medicinal products
inflammatory heart
inflammatory
Prior art date
Application number
AT96301438T
Other languages
English (en)
Inventor
Jay Joseph Armstrong
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE252901T1 publication Critical patent/ATE252901T1/de

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B25HAND TOOLS; PORTABLE POWER-DRIVEN TOOLS; MANIPULATORS
    • B25JMANIPULATORS; CHAMBERS PROVIDED WITH MANIPULATION DEVICES
    • B25J13/00Controls for manipulators
    • B25J13/08Controls for manipulators by means of sensing devices, e.g. viewing or touching devices
    • B25J13/085Force or torque sensors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B25HAND TOOLS; PORTABLE POWER-DRIVEN TOOLS; MANIPULATORS
    • B25JMANIPULATORS; CHAMBERS PROVIDED WITH MANIPULATION DEVICES
    • B25J13/00Controls for manipulators
    • B25J13/08Controls for manipulators by means of sensing devices, e.g. viewing or touching devices
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B25HAND TOOLS; PORTABLE POWER-DRIVEN TOOLS; MANIPULATORS
    • B25JMANIPULATORS; CHAMBERS PROVIDED WITH MANIPULATION DEVICES
    • B25J3/00Manipulators of leader-follower type, i.e. both controlling unit and controlled unit perform corresponding spatial movements
    • B25J3/04Manipulators of leader-follower type, i.e. both controlling unit and controlled unit perform corresponding spatial movements involving servo mechanisms
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B25HAND TOOLS; PORTABLE POWER-DRIVEN TOOLS; MANIPULATORS
    • B25JMANIPULATORS; CHAMBERS PROVIDED WITH MANIPULATION DEVICES
    • B25J9/00Program-controlled manipulators
    • B25J9/10Program-controlled manipulators characterised by positioning means for manipulator elements
    • B25J9/106Program-controlled manipulators characterised by positioning means for manipulator elements with articulated links
    • B25J9/1065Program-controlled manipulators characterised by positioning means for manipulator elements with articulated links with parallelograms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S414/00Material or article handling
    • Y10S414/13Handlers utilizing parallel links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T74/00Machine element or mechanism
    • Y10T74/20Control lever and linkage systems
    • Y10T74/20207Multiple controlling elements for single controlled element
    • Y10T74/20305Robotic arm

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Robotics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Human Computer Interaction (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Packaging Of Machine Parts And Wound Products (AREA)
  • Medicinal Preparation (AREA)
AT96301438T 1995-03-09 1996-03-04 Arzneimittel zur behandlung von entzündlichen herzkrankheiten ATE252901T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/401,747 US5496832A (en) 1995-03-09 1995-03-09 Method of treating cardiac inflammatory disease

Publications (1)

Publication Number Publication Date
ATE252901T1 true ATE252901T1 (de) 2003-11-15

Family

ID=23589066

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96301438T ATE252901T1 (de) 1995-03-09 1996-03-04 Arzneimittel zur behandlung von entzündlichen herzkrankheiten

Country Status (22)

Country Link
US (1) US5496832A (de)
EP (1) EP0730864B1 (de)
JP (1) JPH08245387A (de)
KR (1) KR100449194B1 (de)
CN (1) CN1180774C (de)
AR (1) AR002713A1 (de)
AT (1) ATE252901T1 (de)
AU (1) AU695664B2 (de)
BR (1) BR9600969A (de)
CA (1) CA2170818A1 (de)
CY (1) CY2436B1 (de)
DE (1) DE69630479T2 (de)
DK (1) DK0730864T3 (de)
ES (1) ES2210339T3 (de)
HU (1) HUP9600596A3 (de)
IL (1) IL117417A (de)
NZ (1) NZ286148A (de)
PT (1) PT730864E (de)
SI (1) SI0730864T1 (de)
TW (1) TW431887B (de)
UA (1) UA29484C2 (de)
ZA (1) ZA961927B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
IT1289815B1 (it) * 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
ATE411321T1 (de) 2000-09-19 2008-10-15 Wyeth Corp Wasserlösliche rapamycin-ester
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
US6534693B2 (en) 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
DK1419154T3 (da) 2001-08-22 2006-01-09 Wyeth Corp Rapamycin-29-enoler
EP1419153A1 (de) 2001-08-22 2004-05-19 Wyeth Rapamycindialdehyde
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
DE60221287D1 (de) 2001-11-08 2007-08-30 Atrium Medical Corp Intraluminale vorrichtung mit einer ein therapeutisches-mittel enthaltenden beschichtung
AU2002352726A1 (en) 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
PT1478648E (pt) 2002-02-01 2014-07-15 Ariad Pharma Inc Compostos contendo fósforo e suas utilizações
JP4265888B2 (ja) * 2002-06-12 2009-05-20 株式会社リコー 画像形成装置
AR040693A1 (es) 2002-07-30 2005-04-13 Wyeth Corp Formulaciones parenterales
US7438925B2 (en) * 2002-08-26 2008-10-21 Biovention Holdings Ltd. Drug eluting coatings for medical implants
AU2003272489B2 (en) * 2002-09-17 2008-11-13 Wyeth Granulated formulation of the rapamycin ester CCI779
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
DE602004004520T2 (de) * 2003-04-22 2007-11-08 Wyeth Antineoplastische zusammensetzungen
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US20060067977A1 (en) 2004-09-28 2006-03-30 Atrium Medical Corporation Pre-dried drug delivery coating for use with a stent
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
EP1811935B1 (de) 2004-09-28 2016-03-30 Atrium Medical Corporation Wärmegehärtetes gel und herstellungsverfahren
US9592324B2 (en) 2006-11-06 2017-03-14 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US20080214595A1 (en) * 2005-05-16 2008-09-04 Seigo Izumo Use Of Rapamycin Derivatives For The Treatment And/Or Prevention Of Cardiovas Cular Disorders
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
AU2006304590A1 (en) 2005-10-15 2007-04-26 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
WO2007059106A2 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of mntor inhibitor to treat patients with cancer
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
EP2083834B1 (de) 2006-09-13 2017-06-21 Elixir Medical Corporation Makrozyklische lactonverbindungen und verfahren zu ihrer verwendung
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US20100086579A1 (en) * 2008-10-03 2010-04-08 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
BRPI1010655A2 (pt) * 2009-04-10 2019-09-03 Qi Haiyan novos agentes antienvelhecimento e métodos para identificá-los
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US10322213B2 (en) 2010-07-16 2019-06-18 Atrium Medical Corporation Compositions and methods for altering the rate of hydrolysis of cured oil-based materials
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
WO2016040570A2 (en) 2014-09-12 2016-03-17 Children's Medical Center Corporation Dietary emulsion formulations and methods for using the same
CN105663027B (zh) * 2016-04-01 2018-12-18 中国人民解放军广州军区武汉总医院 西罗莫司外用制剂、其制备方法及用途
US20210161868A1 (en) * 2018-04-25 2021-06-03 Beth Israel Deaconess Medical Center, Inc. Anti-inflammatory therapy in arrhythmogenic cardiomyopathy (acm)
EP4076399A1 (de) * 2019-12-19 2022-10-26 TriviumVet Dac Rapamycin enthaltende tierarzneirezepturen und verfahren zu deren verwendung zur behandlung von tierkrankheiten

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
IL101353A0 (en) * 1991-04-03 1992-11-15 American Home Prod Pharmaceutical compositions for treating diabetes
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease

Also Published As

Publication number Publication date
ZA961927B (en) 1997-09-08
KR960033460A (ko) 1996-10-22
CA2170818A1 (en) 1996-09-10
TW431887B (en) 2001-05-01
AU4798396A (en) 1996-09-19
CN1180774C (zh) 2004-12-22
DE69630479D1 (de) 2003-12-04
NZ286148A (en) 2000-02-28
EP0730864B1 (de) 2003-10-29
HU9600596D0 (en) 1996-05-28
EP0730864A1 (de) 1996-09-11
DE69630479T2 (de) 2004-07-29
CY2436B1 (en) 2004-11-12
IL117417A (en) 1999-08-17
HUP9600596A2 (en) 1997-01-28
KR100449194B1 (ko) 2005-09-05
JPH08245387A (ja) 1996-09-24
AR002713A1 (es) 1998-04-29
IL117417A0 (en) 1996-07-23
PT730864E (pt) 2004-02-27
CN1143497A (zh) 1997-02-26
ES2210339T3 (es) 2004-07-01
SI0730864T1 (en) 2004-02-29
DK0730864T3 (da) 2004-03-01
HUP9600596A3 (en) 1998-07-28
UA29484C2 (uk) 2000-11-15
US5496832A (en) 1996-03-05
BR9600969A (pt) 1997-12-30
HK1009939A1 (en) 1999-06-11
AU695664B2 (en) 1998-08-20

Similar Documents

Publication Publication Date Title
ATE252901T1 (de) Arzneimittel zur behandlung von entzündlichen herzkrankheiten
DE69315257D1 (de) Simethicon enthaltende Arzneimittel zur Behandlung gastrointestinaler Störungen
ATE195527T1 (de) Neue steroidester zur behandlung von hauterkrankungen
NO965377L (no) Indolinonforbindelser for behandling av sykdommer
ATE256463T1 (de) Pharmazeutische zubereitung zur verwendung in der behandlung von diabetes
FI952721A7 (fi) Aine maksa-sappi-sairauksien hoitamiseksi
NO924461D0 (no) Dipyridamol for behandling av proliferaktive sykdommer
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
FI943625A0 (fi) Menetelmiä tulehduksellisten ihotautien hoitamiseksi
DE69600100D1 (de) Puderquaste zur örtlichen Behandlung der Haut
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
ATE269077T1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
ATE295174T1 (de) Arzneimittel zur behandlung von bluthochdruck
FI933902A7 (fi) Substituoidut sykloheksaanijohdannaiset sairauksien hoitamiseksi
DE69532066D1 (de) Arzneimittel zur Behandlung von Restenosis und Gefässsklerose
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
DE69600983D1 (de) Kapselpräparate zur Behandlung von Pflanzen
ATE198751T1 (de) Azoderivate von 5-aminosalicylsäure zur behandlung von enzündlichen darmerkrankungen
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE69937692D1 (de) Arzneimittel zur behandlung der hemicrania
NO973193D0 (no) Kollagen-baserte metoder og formuleringer for behandling av immune system-medierte sykdommer
DE69738320D1 (de) Verwendung von pyrolidin-derivaten zur herstellung von arzneimitteln zur behandlung von drogenmissbrauch
DE69739190D1 (de) Arzneimittel zur behandlung von oculären kreislauferkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0730864

Country of ref document: EP

REN Ceased due to non-payment of the annual fee